secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001628280-24-041646
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal and Metsera partner on obesity drug portfolio; new India facilities cost $150-200M
--------------------------------------------------------------------------------

- Amneal to build two manufacturing facilities in India for peptide synthesis and sterile fill-finish; net cost $150-200M over 4-5 years.
- Amneal named Metsera's preferred supply partner for US and Europe; licensed to commercialize in select emerging markets.
- Metsera's lead candidate MET-097 (GLP-1 injectable) showed durable weight loss in Phase 1; expected first drug under collaboration.
- Collaboration leverages Amneal's existing manufacturing network and provides a new high-growth vector in the obesity market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000162828024041646/0001628280-24-041646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000162828024041646/amrx-20241001.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-041646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer